Posted by Michael Wonder on 21 Jul 2020
ICER publishes evidence report on obeticholic acid for the treatment of non-alcoholic steatohepatitis
21 July 2020 - Given the FDA’s recent decision to not grant accelerated approval for the treatment, ICER has canceled its August public meeting.
The Institute for Clinical and Economic Review today released an Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (Intercept Pharmaceuticals) for the treatment of non-alcoholic steatohepatitis with fibrosis.
